Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds

Advertising today archive

3179 PWToday Stories

NICE Rejects Bayer's Nexavar

09 Sep 09

In what seems to be a troubling sign for cancer patients in the UK, the National Institute for Clinical Excellence (NICE) has once again turned town Bayer's Nexavar for the treatment of liver cancer in the UK. Advanced hepatocellular carcinoma (HCC), the form of liver cancer that the drug treats, accounts for up to 90 of all tumors. The drug was earlier turned down for treatment for kidney cancer, too. The rejection comes despite an offer of lower costs by the German drugs giant. Nexavar, or sorafenib generically, is one of Bayer's top drugs and the firm has confidence that it can generate up to 2 billion euros ($2.9 billion) a year from sales of the treatment.

A spokesperson for Bayer said: "We thought we had satisfied NICE's criteria for how Nexavar would be assessed -- however, the goal posts appeared to have moved", adding that "This proposal by NICE conflicts dramatically with the government's strategy to bring UK cancer outcomes in-line with the rest of Europe, where Nexavar is already widely available in countries such as France, Germany, Spain, Italy, Romania, and Greece." The Chief Executive of the British Liver Trust, said: "This is a very poor decision for patients with HCC in the UK. Liver cancer is a major concern for the trust, and the trust calls for improvements throughout the liver cancer patient pathway".

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.